Becoming my favorite setup October 11, 2023  [Hot Stock]( I [Surprise]( ð *Sponsored by Sica Media As we start today, I continue to have bonds in focus. I know, this is boring âold guyâ stuff, but if you learn to read the quiet whisperings of the stock marketâs tea leaves, you will become a much better trader. And right now, bonds are driving the ship⦠so we better pay attention! This morning, TLT is breaking above the key $87 level I have been banging the table on for weeks now (make sure you are paying attention to that). I think this is going to keep a bid under stocks, we will likely see the market dips bought, and we think the rally will move even higher from here. This is a âgreen lightâ time in the market for my personal trading. If you are like me, you are scouring the market for new ideas right now. Well, I donât see many setups better than what I am seeing with NLS Pharmaceuticals (NLSP) right now. I know it is a small stock that is trading under a buck â but that is exactly what I am drawn to. Those are the types of stocks that can make incredible percentage gain moves in a very short period of time. Just this morning in pre-market we already saw NLSP make a 12% move, and that is on top of the nearly 10% gain it posted yesterday. Let me get out my calculator really quick ð§®â¦ From my basic math, that looks like a 20%+ move for NLSP within a day. Congrats to everyone who paid attention to this yesterday morning when I brought it to your attention. You have been rewarded with a delicious stock move, all for simply opening an email. What a world we live in. Now, the question on everyoneâs mind is where are things headed from here? Well, no one ever knows for sure, but what I do know is that I am seeing one of the strongest indicators in the entire market right now. See this cluster of âGOâ signals? When I look at 1000âs of charts, in any timeframe, this is what I typically see before a major trend reversal. And if history holds up, NLSP has had a history of making big, double-digit moves when it decides to reverse course. I would certainly rather be early in a move like that rather than waiting on the sidelines and watching it happen without me. If you havenât taken a look at NLSP yet, Iâd strongly encourage you to pull it up on your screen and see what you think. Yesterday, I gave the following baseball analogy about what I look for when it comes to a great trade setup. A âgreat trade setupâ is when I see an opportunity so obvious, it is stupid not to take a swing. It may not work all of the time, but it is always worth a swing from me. I wait for what I call âfat pitchesâ to come along â high-confidence moves based on solid technicals. Well, folks, that is exactly what I saw coming over the plate yesterday, and it is building today. When you see a nice, slow, fat pitch coming your way⦠all you need to do is get a plan and take a swing. Let me explain⦠I first wrote to you about Swiss-based NLS Pharmaceutics (NASDAQ: NLSP) in late-August. As I wrote at the time, âWe donât often see setups like these so it is imperative to take full advantage when they do come around.â If you paid attention to that, you then witnessed NLSP make a double-digit move higher over the next week, before consolidating one more time, and ultimately making a clear breakout over 20% higher, much like we just saw in the last 24-hours. Well folks, this is the reason Iâve stayed tuned to the NLSP story since then and right now my favorite indicators are signaling that we may be on the cusp of another major breakout. Revisit this chart I shared with you yesterday before the market opened: Thatâs the analysis of an advanced, computer-generated algorithm that considers over a dozen different momentum indicators to determine the most likely trend going forward. This âgo/no goâ algorithm is the single-best computer-generated indicator I look to for confirmation on when to enter a trade. When I layer it on top of my own indicators and analysis, it gives me a very high-level of confidence in my personal trading.. As you can see, Iâve highlighted several very quick and sizable recent gains⦠A 66% move in 4 days⦠a 40% move in a single day⦠a 22% move in 2 days⦠and a 42% move in 5 days⦠â¦And this is all just since June! In three of those reversals, you can see multiple, conflicting go/no-go markers along the trendline just before the chart legged up. These mixed signals are a classic indicator Iâve seen play out countless times before reversals. And that brings me to what I am seeing today. Those conflicting go/no-go markers suggest we could be very close to an inflection point, just like when I first alerted you to NLSP on August 22, before it made a 42% move higher. Looking at the chart of the last week, Iâm not surprised those markers are flashing: As you can see, by the end of last week, NLSP was trading flat overall, but had tested new highs that were at least 10% moves up throughout the week. Yesterday morning kicked off with yet another 10% spike before settling in at recent support above $.70. This is often what the valley of a reversal will look like. Rarely will a stock rocket straight up at the end of a weeks-long drawdown. Instead, it will test the breakout repeatedly before making its ultimate swing. This is a great indication that an upside move could be coming, and that it could be dramatic. One of the most important items you should read on NLSP right now is the recent [shareholder letter]( their CEO recently issued. On top of the $10M private placement (which should firm up the companyâs finances), one of the biggest news items I found that most traders overlooked is this line: âAt this time we have received several non-binding term sheets for a potential partnership agreement within the pharmaceutical industry.â Take it how you will, but that sounds to me like NLSP could be very close to securing a game-changing partnership to help get their key product to market. That actually should not be surprising considering since in July of 2023, NLSP announced that the Phase 3 clinical trial (called the AMAZE Program) protocol to evaluate the safety and efficacy of Mazindol ER in patients with narcolepsy type 1 received approval from the independent Institutional Review Board ("IRB"). On top of that, On August 25, 2023, NLSP submitted a fast-track designation application for Mazindol ER for the treatment of narcolepsy to the FDA. That is HUGE. You see, standard reviews by the FDA for drug approval generally take about one year. A medicine that receives âFast Track Designationâ can be on the market within six months of the regulatory application. Fast-Track approval could literally change the fortunes of NLSP shareholders⦠overnight. Itâs not only my technical analysis that gives NLSP a âthumbs up ðâ right now. As further confirmation, Yahoo! Finance is lighting up âbullishâ on the slow stochastic oscillator, which you can read about in detail [here](. In brief, the slow stochastic helps us distinguish signal from noise by comparing the latest closing price to the highs and lows over the last 14 periods. This popular indicator is also giving a green light. Checking the news cycle, we just received [this report]( from Fintel last week: - The average one-year price target for NLS Pharmaceutics (NLSP) has been revised to $9.94 / share. This is an increase of 24.47% from the prior estimate of 7.99 dated August 31, 2023. - The price target is an average of many targets provided by analysts. The latest targets range from a low of 6.06 to a high of 14.18 / share. The average price target represents an increase of 1,286.84% from the latest reported closing price of 0.72 / share. If the analysts are right, the average price target represents a 10-bagger opportunity ð° Of course, since NLSP is a clinical-stage pharmaceutical company, a lot of that depends on the success of the companyâs drug trials⦠Between the explosive technical setup we are seeing along the the potentially game-changing developments recently, these things could all be catalysts for a serious rocket-ride for the stock ð. Will that happen for sure? The future is never certain in the markets. There is always risk. But as I said, based on my analysis, this is looking like a pitch right over the plate. You must do your own research, however. Iâm mortal, after all, and I want all my readers to get used to studying charts, examining fundamentals, and ultimately making up their own minds. Nothing is ever guaranteed in life or trading, so make wise decisions that consider your own personal risk profile. I suggest first checking out the NLS Pharmaceutics website [here](, and especially browse through the [âInvestors page](â. This is an opportunity that might be gone before you know it, so take the time to learn more about NLSP right now and see if it makes sense for you. From there, youâll want to do an in-depth study of the stockâs chart. Again, the ticker is NLSP. Happy hunting! To Your Success, *This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. Full Disclaimer  Questions or concerns about our products? Email Support@ragingbull.com © Copyright 2022, RagingBull  DISCLAIMER To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull.com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. RagingBull.com, LLC shall be entitled to recover attorneysâ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneysâ fees, costs and disbursements in addition to any other relief to which it may be entitled. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. Update your email preferences or unsubscribe [here]( © 2023 Bullseye Trades 62 Calef Hwy. #233
Lee, NH 03861, United States of America